Linked Life Data

8018099

Source:http://linkedlifedata.com/resource/pubmed/id/8018099

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2A
pubmed:dateCreated
1994-7-27
pubmed:abstractText
A new cognition-enhancing agent, nefiracetam (N-(2,6-dimethylphenyl)-2- (2-oxo-1-pyrrolidinyl) acetamide, DM-9384, CAS 77191-36-7) was studied for mutagenicity by using the following short-term in vitro and in vivo tests: 1. reverse mutation test (Ames method) on S. typhimurium and E. coli, 2. cytogenetic test on Chinese hamster cells, and 3. mouse micronucleus test. In the cytogenetic study, nefiracetam caused a slight but significant increase of chromosomal aberration at the highest dose in the 48 h treatment group, but no mutagenicity was observed with the same indicator in the in vivo micronucleus test. Furthermore, nefiracetam did not show any positive response in the reverse mutation test. These results suggest that nefiracetam has no biologically significant respectively relevant mutagenic potential.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0004-4172
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
251-3
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Mutagenicity study of the new cognition-enhancing agent nefiracetam.
pubmed:affiliation
Drug Safety Research Center, Developmental Research Laboratories, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
pubmed:publicationType
Journal Article, In Vitro